FOLH1 and prostate cancer: For example, when selecting a prostate cancel model for PSMA, LNCaP and CWR22Rv1 prostate cancer cells endogenously exhibit significant PSMA expression, while PC3 and DU145 prostate cancer cells do not express PSMA 135.